Roots Analysis has announced theaddition of “GlobalPsychedelic Therapeutics Market,2020-2030” report to its list ofofferings.
The report featuresan extensive study of the current market landscape, offering an informedopinion on the likely adoption of these therapies over the next decade. Itfeatures an in-depth analysis, highlighting the capabilities of variousstakeholders engaged in this domain. In addition to other elements, the studyincludes:
§ A detailed assessmentof the current market landscape of drug developers engaged in the developmentof psychedelic therapeutics.
§ Tabulated profiles ofprominent psychedelic therapeutics developers. shortlisted on the basis of thenumber of pipeline products).
§ Detailed profiles ofdevelopers of next generation immune checkpoint modulators (shortlisted onthe basis having two or more psychedelics-based therapies in phase II clinicalstudies and above).
§ An insightfulanalysis of clinical trial sites where the studies have been / are beingconducted for evaluation of various psychedelic therapeutics.
§ A list of key opinionleaders (KOLs) within this domain, and detailed 2×2 matrices to assess therelative experience of key individuals who were shortlisted based on theircontributions (in terms of involvement in various clinical studies) to thisfield.
§ A detailed analysisof nearly 545 grants that have been awarded to research institutes engaged inpsychedelic therapeutics projects, in the period between 2015 and 2020 (tillMay).
§ An analysis of thepartnerships that have been established in the recent past (2017-2020 tillMay),
§ A detailed analysisof the various mergers and acquisitions that have taken place in this domain,highlighting the trend in the number of companies acquired between 2017-2020.
§ A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)
§ TargetDisease Indication
§ Anxiety and Depression
§ Trauma
§ Pain Disorder
§ Sleep relatedDisorder
§ Originof Psychedelic Substance
§ Natural
§ Synthetic
§ Typeof Psychedelic Substance
§ Gamma-hydroxybutyrate
§ Ketamine
§ MDMA
§ Psilocybin
§ Routeof Administration
§ Oral
§ Intranasal
§ Sublingual
§ KeyGeographies
§ North America
§ Europe
§ Asia-Pacific
Transcriptsof interviews held with the following senior level representatives ofstakeholder companies
§ Andrew Chadeayne (Founder &Chief Executive Officer, CaaMTech)
§ Janakan Krishnarajah (ChiefOperating Officer and Chief Medical Officer, iX Biopharma)
§ Alexander Speiser (ChiefOperating Officer, Orthogonal Thinker)
§ Tracy Cheung, (ChiefCommunications Officer, COMPASS Pathways)
Key companies covered in the report
§ Celon Pharma
§ iX Biopharma
§ MAPS Public Benefit
§ MindMed
§ Janssen Pharmaceuticals
§ Jazz Pharmaceutical
For additionaldetails, please visit
https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.htmlor email sales@rootsanalysis.com
You mayalso be interested in the following titles:
1. EndocannabinoidSystem Targeted Therapeutics Market, 2020-2030
2. DepressiveDisorders (Major Depression, Bipolar Disorder, Postpartum Depression,Treatment-Resistant Depression and Others): Pipeline Review, DeveloperLandscape and Competitive Insights, 2019
3. Alzheimer'sDisease: Pipeline Review, Developer Landscape and Competitive Insights
4. NeoantigenTargeted Therapies Market, 2019-2030
5. Blood-BrainBarrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive DrugDelivery Technology Platforms and Therapeutics
About Roots Analysis
Roots Analysis is oneof the fastest growing market research companies, sharing fresh and independentperspectives in the bio-pharmaceutical industry. The in-depth research,analysis and insights are driven by an experienced leadership team which hasgained many years of significant experience in this sector. If you’d like helpwith your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots AnalysisPrivate Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
